Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2026-02-28 @ 6:58 AM
Study NCT ID:
NCT01935934
Status:
COMPLETED
Last Update Posted:
2025-10-01
First Post:
2013-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Endometrial Adenosquamous Carcinoma | View |
| None | Endometrial Clear Cell Adenocarcinoma | View |
| None | Endometrial Mixed Cell Adenocarcinoma | View |
| None | Endometrial Serous Adenocarcinoma | View |
| None | Metastatic Endometrioid Adenocarcinoma | View |
| None | Recurrent Malignant Uterine Corpus Neoplasm | View |
| None | Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 … | View |
| None | Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 … | View |
| None | Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 … | View |
| None | Uterine Corpus Carcinosarcoma | View |
Keywords: